Novo Nordisk STEP Young phase 3 data: 40.4% ...

Semaglutide cut childhood obesity rates by 40.4% in phase 3 trial; safety profile unchanged.

What the company is saying

Novo Nordisk is highlighting topline results from the STEP Young phase 3 trial, positioning semaglutide as a potential solution for paediatric obesity where treatment options are limited. The company emphasises that 40.4% of children treated with semaglutide plus lifestyle changes were no longer classified as obese after 68 weeks, compared to 0% in the placebo group. Messaging stresses the severity of the trial population, with over 85% having class II or III obesity at baseline, and frames the results as a breakthrough for a high-risk group. Safety is addressed with the claim that no new concerns emerged and that the profile matches prior adult and adolescent data, but without quantitative detail. The company references the global scale of the problem—177 million children with obesity in 2025, rising to 228 million by 2040—to underscore the potential impact. Statements from senior executives and external experts are used to reinforce credibility and the urgency of intervention.

What the data suggests

The disclosed figures show that semaglutide, combined with lifestyle modification, resulted in 40.4% of treated children aged 6 to under 12 years no longer meeting the CDC definition of obesity after 68 weeks, versus 0% in the placebo group. The trial enrolled 165 children, with more than 85% classified as having severe (class II or III) obesity at baseline. Dosing was weight-based, up to 1.7 mg or 2.4 mg weekly. The primary endpoint—BMI reduction at week 68—was met, but no absolute or relative BMI change values are provided. Safety is described as consistent with prior studies, with no new concerns for growth or puberty, but no incidence rates or adverse event data are disclosed. The announcement does not include financial figures, regulatory status, or commercial timelines. Global prevalence data—177 million children with obesity in 2025, projected to 228 million by 2040—are cited, but these do not relate directly to trial outcomes.

Analysis

The announcement presents topline results from a phase 3 paediatric obesity trial, with clear disclosure that the primary endpoint was met and specific numerical outcomes (e.g., 40.4% of treated children no longer classified as obese after 68 weeks vs 0% for placebo). The language is generally proportionate to the evidence, focusing on realised clinical outcomes rather than speculative future benefits. While some forward-looking statements are present (e.g., projections of global obesity prevalence, potential long-term health benefits, and upcoming detailed data presentations), these are secondary to the main, realised trial results. No exaggerated claims about commercialisation, regulatory approval, or financial impact are made. There is no indication of a large capital outlay or delayed benefit realisation. The main gap is the absence of detailed safety data and financial metrics, but this is typical for a topline clinical trial release and does not constitute hype.

Risk flags

• ●Absence of detailed safety data: The announcement claims safety is consistent with prior trials but provides no quantitative adverse event rates or breakdowns, leaving uncertainty about tolerability and rare risks in this young population.
• ●No regulatory or commercial pathway disclosed: The company does not state whether or when it will seek approval for paediatric use, so the timeline and likelihood of market access remain undefined.
• ●Limited efficacy detail: Only the headline obesity resolution rate is provided; there is no information on mean BMI reduction, subgroup responses, or durability beyond 68 weeks, which limits assessment of clinical significance.
• ●Potential generalisability risk: The trial population was highly selected (85% with severe obesity), so results may not apply to children with less severe forms or different demographic backgrounds.
• ●Reliance on future disclosures: Full efficacy and safety data are deferred to a conference presentation, so investors cannot yet assess the robustness or completeness of the findings.

Bottom line

Novo Nordisk's phase 3 STEP Young trial shows that semaglutide plus lifestyle modification enabled 40.4% of treated children to move below the obesity threshold after 68 weeks, compared to none on placebo, in a population where over 85% had severe obesity. The topline result is clinically meaningful, but the lack of detailed safety, subgroup, and durability data means the full risk-benefit profile is not yet clear. No information is provided on regulatory submission plans or commercial timelines, so the path to monetisation is uncertain. The company positions semaglutide as a potential major advance in paediatric obesity, but investors will need to see the detailed data at ObesityWeek 2026 and any subsequent regulatory updates before assessing the true commercial opportunity. The key takeaway is that semaglutide demonstrated a strong efficacy signal in a difficult-to-treat group, but critical details for investment decisions are still pending.

Announcement summary

(LSE/AIM:0QIU) Novo Nordisk announced first results from the STEP Young phase 3 trial, evaluating once-weekly subcutaneous semaglutide in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years old with obesity. The trial met its primary endpoint, demonstrating superior body mass index (BMI) reduction at week 68 in the group taking semaglutide compared with the placebo group. 40.4% of the children treated with semaglutide were no longer classified as having obesity after 68 weeks, compared with 0% in the placebo group. At baseline, more than 85% of the children had either class II or III severe obesity, corresponding to a BMI above or equal to 35 and 40 in adults, respectively. The STEP Young trial was a randomised, double-blind, placebo-controlled, multinational trial involving 165 children with obesity aged 6 to under 12 years, both in combination with reduced-calorie diet and increased physical activity. The children received a maximum dose of either 1.7 mg or 2.4 mg of semaglutide, based on their weight at the start of the trial. The overall safety and tolerability of semaglutide observed in STEP Young were consistent with previous Novo Nordisk paediatric and adult trials with semaglutide and liraglutide, and no new safety concerns were identified. No safety concerns were identified for growth or pubertal development. Detailed STEP Young results will be presented at The Obesity Society’s annual meeting ObesityWeek 2026, 14-17 November in Washington DC, United States. An estimated 177 million children aged 5 to 19 were living with obesity in 2025, and this figure is projected to rise to 228 million by 2040.

Disagree with this article?